Results 141 to 150 of about 54,763 (333)
Biglycan : a multivalent proteoglycan providing structure and signals [PDF]
, 2013 Research over the past few years has provided fascinating results indicating that biglycan, besides being a ubiquitous structural component of the extracellular matrix (ECM), may act as a signaling molecule.
Năstase, Mădălina-Viviana +2 more
core
Ineffectiveness of Selenium in the Treatment of Nutritional Muscular Dystrophy in the Rabbit [PDF]
, 1957 H. H. Draper
openalex +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Skeletal muscle ischaemia/reperfusion (I/R) injury remains a clinically significant condition characterized by muscular dystrophy. Although ozone therapy has shown protective potential against I/R injury in animal models of various organs including skeletal muscle, its precise mechanistic underpinnings require further elucidation.
Hui‐Zhuang Guo +2 more
wiley +1 more source
PATHOLOGY OF PSEUDOHYPERTROPHIC MUSCULAR DYSTROPHY [PDF]
, 1908 O. P. Johnstone
openalex +1 more source
Association of Laryngeal Dystonia With Common Neurologic Disorders
The Laryngoscope, EarlyView.ABSTRACT Objective Laryngeal dystonia is a heterogenous disorder consisting of involuntary spasms of laryngeal muscles. There are multiple forms including adductor, abductor, and mixed phenotypes. The disorder is thought to be multifactorial, with various reported associations with family history of dystonia or movement disorders.
Brandon LaBarge +2 more
wiley +1 more source
Cases of Pseudo-Hypertrophic Paralysis and other Forms of Progressive Muscular Dystrophy [PDF]
, 1898 Jelliffe
openalex +1 more source
Case of Pseudo-Hypertrophic Muscular Dystrophy Associated with Amentia [PDF]
, 1915 E. G. Fearnsides
openalex +1 more source
Genetic Risk Factors in Normal Pressure Hydrocephalus: What We Know and What Is Next
Movement Disorders, EarlyView.Abstract Knowledge of the genetic factors in normal pressure hydrocephalus (NPH) is rapidly evolving, with significant advances in recent years. We conducted a systematic review examining genetic contributions to NPH risk. Ovid Embase, Ovid Medline, Web of Science, and Cochrane Central were searched from inception through October 14, 2024, for human ...
Camila C. Piccinin +9 more
wiley +1 more source
Muscle &Nerve, EarlyView.A total of 95 ERT‐experienced adults with LOPD were randomized to switch to cipaglucosidase alfa + miglustat or remain on alglucosidase alfa treatment. After 52 weeks, patients remaining on alglucosidase alfa showed worsening or stability for most outcomes, whereas patients who switched to cipaglucosidase alfa + miglustat generally showed stability or ...
Hani Kushlaf +17 more
wiley +1 more source